Compare DHX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | MDWD |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 162.2M |
| IPO Year | 2007 | 2013 |
| Metric | DHX | MDWD |
|---|---|---|
| Price | $4.72 | $12.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.75 | ★ $30.67 |
| AVG Volume (30 Days) | ★ 180.9K | 78.8K |
| Earning Date | 11-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | $2.24 | $34.34 |
| P/E Ratio | $49.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $11.84 |
| 52 Week High | $5.19 | $19.70 |
| Indicator | DHX | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 41.90 |
| Support Level | $4.54 | N/A |
| Resistance Level | $4.89 | $14.06 |
| Average True Range (ATR) | 0.22 | 0.50 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 23.39 | 21.79 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.